Trillium Therapeutics (TRIL) is Initiated by Ladenburg Thalmann to Buy, Price Target at $18

Trillium Therapeutics (TRIL) was Initiated by Ladenburg Thalmann to “Buy” and the brokerage firm has set the Price Target at $18. Ladenburg Thalmann advised their investors in a research report released on Aug 3, 2016.

Trillium Therapeutics closed down -0.28 points or -2.95% at $9.21 with 32,525 shares getting traded on Tusday. Post opening the session at $9.33, the shares hit an intraday low of $8.91 and an intraday high of $9.39 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

Trillium Therapeutics

Leave a Reply

Trillium Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Trillium Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.